On June 4, 2015 Navidea Biopharmaceuticals reported that four presentations of Manocept data from Kaposi’s Sarcoma (KS) studies are scheduled at the 18th International Workshop on Kaposi’s Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida from June 30 – July 3, 2015 (Press release, Navidea Biopharmaceuticals, JUN 4, 2015, View Source;p=RssLanding&cat=news&id=2056585 [SID:1234505429]). This research highlights a very likely new approach to the origin of KS supported by preclinical and clinical imaging studies. In addition, data will be presented demonstrating the therapeutic potential for Manocept therapeutic conjugates. MT1001 is a proprietary agent designed to target cells expressing the mannose receptor (CD206) and destroy the cell and its contents. Data will be presented demonstrating MT1001’s ability to target KS and KS tumor-associated macrophages by selectively binding to CD206. Details of the presentations are listed below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Session:
Date: July 1, 2015
Title: In Vivo Localization and Potential for Therapeutic Targeting of Kaposi’s Sarcoma (KS) With A Novel CD206 Localizing Agent
Authors: M McGratha,b*, J Zhanga, T Maurera, S Behra, B Abbruzzesec, J Sandersc, P Braccia,b, FO Copec (*Presenter)
aUniv of California-San Francisco; bAIDS & Cancer Specimen Resource, SFGH c Navidea/Macrophage Therapeutics
Poster Session:
Date: July 1, 2015
Title: Imaging and Therapeutic Potential for Kaposi’s Sarcoma (KS) In Non-Cutaneous Foci with a Novel CD206 Localizing Agent
Authors: B Abbruzzesea*, FO Copea, J Zhangb, T Maurerb, S Behrb, J Sandersa, P Braccib,c, M McGrathb,c (*Presenter)
aNavidea/Macrophage Therapeutics; bUniv of California-San Francisco; cAIDS & Cancer Specimen Resource, SFGH
Poster Session:
Date: July 1, 2015
Title: Kaposi’s Sarcoma (KS) is a Macrophage (MO) Tumor Resulting from a Fusion CD206+MOs and Lymphatic Endothelium
Authors: FO Copea*, J Zhangb, T Maurerb, B Abbruzzesea, J Sandersa, S Behrb, P Braccib,c, M McGrathb,c (*Presenter)
aNavidea/Macrophage Therapeutics; bUniv of California-San Francisco; cAIDS & Cancer Specimen Resource, SFGH
Oral Session: Translational Studies. KSHV Malignancies Associated with HIV/AIDS
Date: July 2, 2015
Title: Manocept, a Novel CD206 Targeting Agent for Potential Use in Treatment of Kaposi’s Sarcoma
Authors: Rongzhen Zhanga, Frederick O. Copeb, Joshua Walkerc, Ken Williamsc, Ekaterina Maidjia, Cheryl Stoddarta, Paige M. Braccia, Michael S. McGratha* (*Presenter)
aUniversity of California San Francisco; bNavidea/Macrophage Therapeutics; cBoston College